AD1
MCID: ALZ002
MIFTS: 21

Alzheimer Disease Type 1 (AD1) malady

Categories: Rare diseases, Genetic diseases, Neuronal diseases, Mental diseases

Aliases & Classifications for Alzheimer Disease Type 1

Aliases & Descriptions for Alzheimer Disease Type 1:

Name: Alzheimer Disease Type 1 50 24 69
Alzheimer Disease 1 50 29
Ad1 50 24
Early-Onset Familial Form of Alzheimer Disease 50
Ad 1 24

Classifications:



Summaries for Alzheimer Disease Type 1

MalaCards based summary : Alzheimer Disease Type 1, also known as alzheimer disease 1, is related to alzheimer disease and early-onset, autosomal dominant alzheimer disease. An important gene associated with Alzheimer Disease Type 1 is APP (Amyloid Beta Precursor Protein). The drugs Dopamine and Donepezil have been mentioned in the context of this disorder.

Related Diseases for Alzheimer Disease Type 1

Symptoms & Phenotypes for Alzheimer Disease Type 1

Drugs & Therapeutics for Alzheimer Disease Type 1

Drugs for Alzheimer Disease Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Early Phase 1 51-61-6, 62-31-7 681
2
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
3
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
4
Memantine Approved, Investigational Phase 4 19982-08-2 4054
5
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
6
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
7
Metformin Approved Phase 4 657-24-9 14219 4091
8
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
9 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
10 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 Neuroprotective Agents Phase 4,Phase 3,Phase 2
13 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Dopamine Agents Phase 4,Phase 3,Early Phase 1
16 Excitatory Amino Acid Antagonists Phase 4,Phase 3
17 Excitatory Amino Acids Phase 4,Phase 3
18 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antiparkinson Agents Phase 4
20 insulin Phase 4,Phase 2
21 Tranquilizing Agents Phase 4,Phase 3,Early Phase 1
22 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1,Early Phase 1
23 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
24 Insulin, Globin Zinc Phase 4,Phase 2
25 Psychotropic Drugs Phase 4,Phase 3,Early Phase 1
26 Antipsychotic Agents Phase 4,Phase 3,Early Phase 1
27 Central Nervous System Depressants Phase 4,Phase 3,Early Phase 1
28 Vasoconstrictor Agents Phase 4,Phase 2,Phase 3
29 Epinephryl borate Phase 4
30 Racepinephrine Phase 4
31
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
32
Galantamine Approved Phase 3 357-70-0 9651 908828, 9651
33
Amphetamine Approved, Illicit Phase 3 300-62-9 5826 3007
34
Flurbiprofen Approved, Investigational Phase 3 5104-49-4 3394
35
Aripiprazole Approved, Investigational Phase 3 129722-12-9 60795
36
Menthol Approved Phase 2, Phase 3,Early Phase 1 2216-51-5 16666
37
Quinidine Approved Phase 3 56-54-2 441074
38
Losartan Approved Phase 2, Phase 3 114798-26-4 3961
39
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
40
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
41
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
42 Brexpiprazole Approved Phase 3 913611-97-9 11978813
43 adderall Phase 3
44 Analgesics Phase 3,Phase 1
45 Dopamine agonists Phase 3
46 Adrenergic Agents Phase 3
47 Cyclooxygenase Inhibitors Phase 3
48 Neurotransmitter Uptake Inhibitors Phase 3
49 Analgesics, Non-Narcotic Phase 3,Phase 1
50 Dexmethylphenidate Hydrochloride Phase 3

Interventional clinical trials:

(show top 50) (show all 144)
id Name Status NCT ID Phase
1 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
2 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4
3 A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints Completed NCT00276510 Phase 4
4 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed NCT00948766 Phase 4
5 Memantine Versus Donepezil in Early Stages of Alzheimer's Disease Completed NCT00505167 Phase 4
6 Corticolimbic Degeneration and Treatment of Dementia Completed NCT00768261 Phase 4
7 Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease Completed NCT00549601 Phase 4
8 Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome Completed NCT01112683 Phase 4
9 SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Recruiting NCT02951559 Phase 4
10 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Recruiting NCT02409238 Phase 4
11 Memantine and Antipsychotics Use Terminated NCT00649220 Phase 4
12 Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) Withdrawn NCT01822951 Phase 4
13 Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type Completed NCT01438060 Phase 3
14 Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's Completed NCT00105547 Phase 3
15 A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease Completed NCT01404169 Phase 3
16 Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease Completed NCT00428090 Phase 3
17 Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease Completed NCT01539031 Phase 3
18 Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease Completed NCT00348140 Phase 3
19 Project ACT: Advancing Caregiving Techniques Completed NCT00259480 Phase 3
20 Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease Completed NCT00646269 Phase 3
21 Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR Completed NCT00393042 Phase 3
22 Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Recruiting NCT02442765 Phase 3
23 Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Recruiting NCT02442778 Phase 3
24 Risk Reduction for Alzheimer's Disease Recruiting NCT02913664 Phase 2, Phase 3
25 Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Recruiting NCT02446132 Phase 3
26 An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Recruiting NCT02245737 Phase 2, Phase 3
27 A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease Recruiting NCT02956486 Phase 3
28 Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia) Recruiting NCT03160027 Phase 2, Phase 3
29 A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_ Recruiting NCT03036280 Phase 3
30 A Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Active, not recruiting NCT01862640 Phase 3
31 Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Active, not recruiting NCT01922258 Phase 3
32 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Active, not recruiting NCT01760005 Phase 2, Phase 3
33 Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type Terminated NCT00160147 Phase 3
34 Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's Terminated NCT00322036 Phase 3
35 A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease Terminated NCT00679627 Phase 3
36 Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease Unknown status NCT00154635 Phase 2
37 A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia Completed NCT02185053 Phase 2
38 Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) Completed NCT00104273 Phase 2
39 A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's Completed NCT01148498 Phase 2
40 A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia Completed NCT01276353 Phase 2
41 Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease Completed NCT00812565 Phase 2
42 Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD) Completed NCT01466088 Phase 2
43 Pioglitazone in Alzheimer Disease Completed NCT00982202 Phase 2
44 Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease Completed NCT01715350 Phase 2
45 TRx0014 in Patients With Mild or Moderate Alzheimer's Disease Completed NCT00515333 Phase 2
46 Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease Completed NCT00842673 Phase 2
47 Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease Completed NCT00842816 Phase 2
48 A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients Completed NCT00141661 Phase 2
49 Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease Completed NCT00501111 Phase 2
50 Development of NIC5-15 in the Treatment of Alzheimer's Disease Completed NCT00470418 Phase 2

Search NIH Clinical Center for Alzheimer Disease Type 1

Genetic Tests for Alzheimer Disease Type 1

Genetic tests related to Alzheimer Disease Type 1:

id Genetic test Affiliating Genes
1 Alzheimer Disease, Type 1 29
2 Alzheimer Disease Type 1 24 APP

Anatomical Context for Alzheimer Disease Type 1

Publications for Alzheimer Disease Type 1

Variations for Alzheimer Disease Type 1

ClinVar genetic disease variations for Alzheimer Disease Type 1:

6 (show all 12)
id Gene Variation Type Significance SNP ID Assembly Location
1 APP NM_000484.3(APP): c.2149G> A (p.Val717Ile) single nucleotide variant Pathogenic rs63750264 GRCh37 Chromosome 21, 27264096: 27264096
2 APP NM_000484.3(APP): c.2149G> T (p.Val717Phe) single nucleotide variant Pathogenic rs63750264 GRCh37 Chromosome 21, 27264096: 27264096
3 APP NM_000484.3(APP): c.2150T> G (p.Val717Gly) single nucleotide variant Pathogenic rs63749964 GRCh37 Chromosome 21, 27264095: 27264095
4 APP NM_000484.3(APP): c.2075C> G (p.Ala692Gly) single nucleotide variant Pathogenic rs63750671 GRCh37 Chromosome 21, 27264170: 27264170
5 APP NM_000484.3(APP): c.2010_2011delGAinsTC (p.Lys670_Met671delinsAsnLeu) indel Pathogenic rs281865161 GRCh37 Chromosome 21, 27269938: 27269939
6 APP NM_000484.3(APP): c.2137G> A (p.Ala713Thr) single nucleotide variant Pathogenic rs63750066 GRCh37 Chromosome 21, 27264108: 27264108
7 APP NM_000484.3(APP): c.2146A> G (p.Ile716Val) single nucleotide variant Pathogenic rs63750399 GRCh37 Chromosome 21, 27264099: 27264099
8 APP NM_000484.3(APP): c.2143G> A (p.Val715Met) single nucleotide variant Pathogenic rs63750734 GRCh37 Chromosome 21, 27264102: 27264102
9 APP NM_000484.3(APP): c.2078A> G (p.Glu693Gly) single nucleotide variant Pathogenic rs63751039 GRCh37 Chromosome 21, 27264167: 27264167
10 APP NM_000484.3(APP): c.2141C> T (p.Thr714Ile) single nucleotide variant Pathogenic rs63750973 GRCh37 Chromosome 21, 27264104: 27264104
11 APP NM_000484.3(APP): c.2140A> G (p.Thr714Ala) single nucleotide variant Pathogenic rs63750643 GRCh37 Chromosome 21, 27264105: 27264105
12 APP NM_000484.3(APP): c.2149G> C (p.Val717Leu) single nucleotide variant Pathogenic rs63750264 GRCh37 Chromosome 21, 27264096: 27264096

Expression for Alzheimer Disease Type 1

Search GEO for disease gene expression data for Alzheimer Disease Type 1.

Pathways for Alzheimer Disease Type 1

GO Terms for Alzheimer Disease Type 1

Sources for Alzheimer Disease Type 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....